NTRK gene fusions: a rough diamond ready to sparkle.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Alimentary pharmacology & therapeutics · 2026
   Review
2. Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review.Japanese journal of clinical oncology · 2025
   Review
3. Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023
   Review
4. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.Cancer biomarkers : section A of Disease markers · 2023
   Article
5. Molecular Pathology of Gastric Cancer.Journal of gastric cancer · 2022
   Review
6. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.International journal of molecular sciences · 2022
   Review
7. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
   Article
8. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.British journal of cancer · 2022
   Article
9. Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.Frontiers in oncology · 2022
   Article
10. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.Journal of cancer research and clinical oncology · 2022
    Article
11. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma.Medical oncology (Northwood, London, England) · 2020
    Review

Corrections and comments

• Comment on
  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as